冠心宁治疗冠心病慢性心力衰竭的疗效及对患者心室重构、hs-CRP、CysC以及NT-proBNP水平的影响

Clinical efficacy of Guanxinning in the treatment of coronary heart disease with chronic heart failure and its effect on ventricular remodeling,hs-CRP,CysC,and NT-proBNP levels

目的观察冠心宁治疗冠心病慢性心力衰竭的疗效,并探讨其对患者心室重构、超敏C反应蛋白(hs-CRP)、胱抑素C(CysC)、N端前脑钠肽(NT-proBNP)水平的影响。方法选择2020年1月至2021年11月西安医学国际中心医院收治的160例冠心病慢性心力衰竭患者为研究对象,按照随机数表法均分观察组和对照组各80例。对照组患者给予常规治疗,观察组患者在此基础上联合冠心宁治疗,疗程3个月。比较两组患者的治疗效果,以及治疗前后的心室重构[心率(HR)、心排血量(CO)、E峰/A峰比值(E/A)]、hs-CRP、CysC、NT-proBNP水平和不良反应发生情况。结果观察组患者的治疗总有效率为95.00%,明显高于对照组的82.50%,差异有统计学意义(P<0.05);治疗后,两组患者的HR均降低,且观察组的HR为(72.78±4.98)次/min,明显低于对照组的(79.41±5.33)次/min,而CO、E/A均升高,且观察组分别为(5.72±0.48)L/min、1.34±0.21,明显高于对照组的(4.88±0.49)L/min、0.98±0.09,差异均有统计学意义(P<0.05);治疗后,两组患者的hs-CRP、CysC、NT-proBNP均降低,且观察组分别为(3.28±0.98)mg/L、(0.71±0.06)mg/L、(309.41±15.31)pg/mL,明显低于对照组的(5.13±0.46)mg/L、(1.01±0.21)mg/L、(398.41±14.35)pg/mL,差异均有统计学意义(P<0.05);观察组患者治疗期间的总不良反应发生率为6.25%,略低于对照组的10.00%,但差异无统计学意义(P>0.05)。结论冠心宁治疗冠心病慢性心力衰竭可促进患者的心室重构,降低hs-CRP、CysC、NT-proBNP水平,临床应用疗效显著,且安全性高,具有临床推广价值。

Objective To observe the efficacy of Guanxinning in the treatment of coronary heart disease with chronic heart failure,and to explore its effects on ventricular remodeling,high-sensitivity C-reactive protein(hs-CRP),Cystatin C(CysC),and N-terminal pro brain natriuretic peptide(NT-proBNP)levels.Methods A total of 160 patients of coronary heart disease with chronic heart failure admitted to Xi'an International Medical Center Hospital from January 2020 to November 2021 were randomly divided into an observation group and a control group,with 80 patients in each group.The patients in the control group were given routine treatment,and those in the observation group were treated with Guanxinning on this basis,for 3 months.After treatment,the curative effects of the two groups were compared,as well as the changes of ventricular remodeling[heart rate(HR),cardiac output(CO),E peak/A peak ratio(E/A)]before and after treatment,hs-CRP,CysC,NT-proBNP levels,and adverse reactions.Results The total effective rate of the ob-servation group was 95.00%,which was significantly higher than 82.50%of the control group(P<0.05).After treatment,HR of patients in both groups decreased,and HR of the observation group was(72.78±4.98)times/min,significantly lower than(79.41±5.33)times/min of the control group;CO and E/A increased,and they were(5.72±0.48)L/min,1.34±0.21 in the observation group,significantly higher than(4.88±0.49)L/min,0.98±0.09 of the control group,with significant differences(P<0.05).After treatment,hs-CRP,CysC,and NT-proBNP in the two groups decreased,and those in the observation group were(3.28±0.98)mg/L,(0.71±0.06)mg/L,(309.41±15.31)pg/mL,respectively,significantly lower than(5.13±0.46)mg/L,(1.01±0.21)mg/L,(398.41±14.35)pg/mL in the control group,with statistically significant differences(P<0.05).The incidence of adverse reactions in the observation group vs the control group during treatment was 6.25%vs 10.00%,with no statistically significant difference(P>0.05).Conclusion Guanxinning can promote ventricular remodeling and reduce the levels of hs-CRP,CysC,and NT-proBNP in patients with coronary heart disease and chronic heart failure,with significant curative effect and high safety,which is worthy of clinical promotion.